Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.68 |
| ▸ | BDNF | P23560 | 3/20 | 0.53 |
| ▸ | MDK | P21741 | 3/20 | 0.53 |
| ▸ | PTN | P21246 | 2/20 | 0.53 |
| ▸ | BMP2 | P12643 | 3/20 | 0.46 |
| ▸ | VEGFA | P15692 | 3/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 3/20 | 0.46 |
| ▸ | SHH | Q15465 | 2/20 | 0.46 |
| ▸ | IFNG | P01579 | 2/20 | 0.44 |
| ▸ | CCL2 | P13500 | 2/20 | 0.44 |
| ▸ | PF4 | P02776 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | BMP6 | P22004 | 1/20 | 0.44 |
| ▸ | CCL11 | P51671 | 1/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.44 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | FGF2 | P09038 | 3/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28227554 | 1.00 | F10 (0.68) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL11557 | 1.00 | F10 (0.68) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL29614646 | 0.99 | F10 (0.67) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL28297524 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| SCHEMBL28294039 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydrochloric Acid SCHEMBL28179031 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydroxyamine SCHEMBL28122321 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Potassium Ion SCHEMBL28270668 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydrochloric Acid SCHEMBL28233049 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 | |
| Hydrochloric Acid SCHEMBL28167126 | 0.99 | F10 (0.66) | F10BDNFMDKPTNBMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2025078632-A1 | METHODS OF PROGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-04-17 | — | — | WO | disclosed |
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2025-03-06 | — | — | US | disclosed |
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2024-10-24 | — | — | US | disclosed |
| CN-118614492-A | In-vitro perfusion preservation solution for improving liver transplantation curative effect of steatosis | 浙江大学 | 2024-09-10 | — | — | CN | disclosed |
| US-20240209370-A1 | METHODS OF MODULATING ALK | Société des Produits Nestlé S.A. (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4380603-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4380685-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117881444-A | Reshaping of injector device stopper features | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117881445-A | Injector device stopper with activatable layer | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-2236158-A1 | New therapeutic approaches for treating neuroinflammatory conditions | Pharnext (FR) | 2010-10-06 | — | — | EP | disclosed |
| CN-101417130-B | Medicine combination for treating II type diabetes and complicating diseases thereof | LUNAN PHARM GROUP CORP | 2010-10-06 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090286881-A1 | SELECTED BETAINES AND THEIR USES | DELL MARKETING L.P. | 2009-11-19 | — | — | US | disclosed |
| CN-101417130-A | Medicine combination for treating II type diabetes and complicating diseases thereof | LUNAN PHARM GROUP CORP (CN) | 2009-04-29 | — | — | CN | disclosed |
| US-20080026474-A1 | ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20060128657-A1 | Selected betaines and their uses | MESSADEK JALLAL | 2006-06-15 | — | — | US | disclosed |
| EP-1660070-A2 | SELECTED BETAINES AND THEIR USES | Messadek, Jallal (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006008173-A2 | PHARMACEUTICAL FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005011645-A2 | SELECTED BETAINES AND THEIR USES | MESSADEK JALLAL (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | PCSK9, APOB, PCSK7 | F10 2186/4885BDNF 669/4885MDK 4486/4885 |
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | SERPINC1, SELP, ADAMTS13 | F10 93/4885BDNF 4876/4885MDK 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.